Your browser doesn't support javascript.
loading
Real-world Uptake of Enfortumab Vedotin plus Pembrolizumab after US Food and Drug Administration Approval Among Patients with Advanced Urothelial Cancer.
Mamtani, Ronac; Ulloa-Pérez, Ernesto; Parikh, Ravi B; Patel, Khilna; Homet Moreno, Blanca; Ramamurthy, Chethan; Li, Haojie; Hubbard, Rebecca A.
Affiliation
  • Mamtani R; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: ronac.mamtani@pennmedicine.upenn.edu.
  • Ulloa-Pérez E; Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, PA, USA.
  • Parikh RB; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA.
  • Patel K; Flatiron Health, Inc, New York, NY, USA.
  • Homet Moreno B; Merck & Co. Inc, Rahway, NJ, USA.
  • Ramamurthy C; Merck & Co. Inc, Rahway, NJ, USA.
  • Li H; Merck & Co. Inc, Rahway, NJ, USA.
  • Hubbard RA; Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, PA, USA.
Eur Urol ; 2024 Aug 21.
Article in En | MEDLINE | ID: mdl-39174408
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Urol Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Urol Year: 2024 Document type: Article Country of publication: